{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:48:43Z","timestamp":1792291723118,"version":"4.4.0"},"reference-count":46,"publisher":"National Academy of Sciences","issue":"51","license":[{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":182,"URL":"https:\/\/www.pnas.org\/site\/aboutpnas\/licenses.xhtml"}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2018,12,18]]},"abstract":"<jats:p>We discuss the need to make economic evaluations of vaccines antimicrobial resistance (AMR)-sensitive and ways to do so. Such AMR-sensitive evaluations can play a role in value-for-money comparisons of different vaccines within a national immunization program, or in comparisons of vaccine-centric and non-vaccine-centric technologies within an anti-AMR program. In general terms, incremental cost-effectiveness ratios and rates of return and their associated decision rules are unaltered by consideration of AMR-related value. The decision metrics need to have their various health, cost, and socioeconomic terms disaggregated into resistance-related subcategories, which in turn have to be measured carefully before they are reaggregated. The fundamental scientific challenges lie primarily in quantifying the causal impact of health technologies on resistance-related health outcomes, and secondarily in ascertaining the economic value of those outcomes. We emphasize the importance of evaluating vaccines in the context of other potentially complementary and substitutable nonvaccine technologies. Complementarity implies that optimal spending on each set of interventions is positive, and substitutability implies that the ratio of spending will depend on relative value for money. We exemplify this general point through a qualitative discussion of the complementarities and (especially the) substitutability between pneumococcal conjugate vaccines and antimicrobial stewardship and between research and development (R&amp;D) of a gonorrhea vaccine versus R&amp;D of a gonorrhea antibiotic. We propose a roadmap for future work, which includes quantifying the causal effects of vaccination and other health technologies on short-term and long-term resistance-related outcomes, measuring the health-sector costs and broader socioeconomic consequences of resistance-related mortality and morbidity, and evaluating vaccines in the context of nonvaccine complements and substitutes.<\/jats:p>","DOI":"10.1073\/pnas.1717161115","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T20:18:38Z","timestamp":1545077918000},"page":"12911-12919","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":69,"title":["Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR"],"prefix":"10.1073","volume":"115","author":[{"given":"J. P.","family":"Sevilla","sequence":"first","affiliation":[{"name":"Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA 02115;"},{"name":"Life Sciences Group, Data for Decisions, LLC, Waltham, MA 02451;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Bloom","sequence":"additional","affiliation":[{"name":"Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA 02115;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cadarette","sequence":"additional","affiliation":[{"name":"Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA 02115;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom;"},{"name":"Modeling and Economics Unit, Public Health England, London NW9 5EQ, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lipsitch","sequence":"additional","affiliation":[{"name":"Center for Communicable Disease Dynamics, Harvard T.H. Chan School of Public Health, Boston, MA 02115;"},{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115;"},{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2018,12,17]]},"reference":[{"key":"e_1_3_3_1_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00428-16"},{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30478-4"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051642"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/508033"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.worlddev.2018.06.022"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.11.027"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00520-6"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2542-5196(18)30186-4"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_3_3_10_2","unstructured":"; World Health Organization Antimicrobial resistance: National action plans. Available at www.who.int\/antimicrobial-resistance\/national-action-plans\/en\/. Accessed September 7 2018. (2018)."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.08.022"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00474-2"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401914"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1901.120741"},{"key":"e_1_3_3_15_2","first-page":"CD003543","article-title":"Interventions to improve antibiotic prescribing practices for hospital inpatients","volume":"2","author":"Davey P","year":"2013","unstructured":"P Davey, , Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2, CD003543 (2013).","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2014.41"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2018.01.002"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.5387\/fms.56.28"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.07.010"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4151"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-015-2109-3"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.01860"},{"key":"e_1_3_3_23_2","unstructured":"C Jiang When penicillin pays: Why China loves antibiotics a little too much. Time . Available at content.time.com\/time\/world\/article\/0 8599 2103733 00.html. Accessed September 14 2018. (January 5 2012)."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gheart.2014.08.009"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijpp.12244"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6645a3"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131156"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00929-17"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv161"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.2016.2562"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2014-051730"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002344"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.3109\/1040841X.2015.1105782"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2012.08.002"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.015"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002366"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2015.02.006"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-017-08323-0"},{"key":"e_1_3_3_39_2","unstructured":"; Gavi The Vaccine Alliance Human papillomavirus vaccine support. Available at https:\/\/www.gavi.org\/support\/nvs\/human-papillomavirus\/. Accessed September 14 2018. (2018)."},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.01.028"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.140900"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/acprof:oso\/9780190492939.001.0001"},{"key":"e_1_3_3_43_2","unstructured":"; iDSI iDSI reference case for economic evaluation. Available at www.idsihealth.org\/resource-items\/idsi-reference-case-for-economic-evaluation\/. Accessed September 7 2018. (2016)."},{"key":"e_1_3_3_44_2","unstructured":"; Harvard T.H. Chan School of Public Health Guidelines for benefit-cost analysis. Available at https:\/\/sites.sph.harvard.edu\/bcaguidelines\/. Accessed September 7 2018. (2018)."},{"key":"e_1_3_3_45_2","unstructured":"; Vaccine Impact Modeling Consortium Model standards. Available at https:\/\/www.vaccineimpact.org\/resources\/3_VIMC_model_standards_201804.pdf. Accessed September 7 2018. (2018)."},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-018-0115-x"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1717161115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T02:08:49Z","timestamp":1649815729000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1717161115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,17]]},"references-count":46,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2018,12,18]]}},"alternative-id":["10.1073\/pnas.1717161115"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1717161115","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,17]]},"assertion":[{"value":"2018-12-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}